Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy
A pharmaceutical grade formulation of cannabidiol (CBD) has been approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome; however, this formulation is not yet available to patients outside the USA. In addition, CBD is thought to have broad anti-seizure properties that may be beneficial for other types of intractable epilepsy.
The aim of this study was to evaluate the efficacy, safety and tolerability of artisanal medical CBD oil in patients with developmental and epileptic encephalopathy (DEE) at the tertiary epilepsy center of Bambino Gesù Children’s Hospital in Rome, Italy.
This was a single-center, prospective, open-label study. Patients aged from 1 to 18 years with DEE and seizures refractory to appropriate antiepileptic drugs (AEDs) and other alternative treatments (i.e., vagal nerve stimulator and ketogenic diet) were included. Crystalline extract CBD powder (98–99% pure) in an oil artisanal formulation was added to the baseline AED regimen at a dosage of 2–5 mg/kg/day divided for twice-daily administration, then up-titrated until intolerance or a maximum dosage of 25 mg/kg/day was reached. Patients were treated for at least 6 months. Efficacy, safety and tolerability of CBD treatment were assessed through the evaluation of seizure frequency and reports of adverse effects.
Twenty-nine patients were enrolled in this study (41.4% male). The mean duration of exposure to artisanal CBD was 11.2 months [range 6–25 months; standard deviation (SD) ± 4.4 months]. Mean age at study enrollment was 9.3 years (range 1.9–16.3 years; SD ± 4.7 years). Eleven out of 29 patients (37.9%) had a ≥ 50% improvement in seizure frequency; one patient became seizure free. None of the patients reported worsening seizure frequency; however, 18 patients (62.1%) experienced no beneficial effect regarding seizure frequency. Adverse effects were reported in seven patients (24.14%), most commonly somnolence, decreased appetite and diarrhea. Adverse events were mild and transient, and no dose modification of CBD or other AEDs was required.
These data suggest that CBD may have beneficial effects in patients with DEE and an acceptable safety profile. Placebo-controlled randomized trials should be conducted to formally assess the safety and efficacy of CBD in patients with DEE.
Compliance with Ethical Standards
This study was not funded.
Conflict of Interest
Nicola Pietrafusa, Alessandro Ferretti, Marina Trivisano, Luca de Palma, Costanza Calabrese, Giusy Carfi’ Pavia, Ilaria Tondo, Simona Cappelletti, Federico Vigevano, and Nicola Specchio have no conflicts of interest.
This trial was conducted in accordance with International Conference on Harmonization Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki.
Written informed consent was obtained from each patient’s parent or primary caregiver before any trial-related procedures were performed.
- 10.GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences announce FDA approval of EPIDIOLEX® (cannabidiol) oral solution—the first plant-derived cannabinoid prescription medicine. https://www.gwpharm.com/about-us/news/gw-pharmaceuticals-plc-and-its-us-subsidiary-greenwich-biosciences-announce-fda. Accessed 15 Nov 2018.
- 14.FDA. 2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm. Accessed 15 Dec 2018.
- 15.GW Pharmaceuticals announces the European Medicines Agency (EMA) accepts Epidiolex® (cannabidiol) Marketing Authorization Application (MAA) for review. https://globenewswire.com/news-release/2018/02/05/1333218/0/en/GW-Pharmaceuticals-Announces-the-European-Medicines-Agency-EMA-Accepts-Epidiolex-Cannabidiol-Marketing-Authorization-Application-MAA-for-Review.html. Accessed 1 Nov 2018.
- 16.Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal. 2016;128:201–9.CrossRefPubMedGoogle Scholar
- 17.Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017;55(10):1555–63.CrossRefPubMedGoogle Scholar
- 18.Calvi L, Pentimalli D, Panseri S, Giupponi L, Gelmini F, Beretta G, Vitali D. Comprehensive quality evaluation of medical Cannabis sativa L. inflorescence and macerated oils based on HS-SPME coupled to GC–MS and LC–HRMS (q-exactive orbitrap®) approach. J Pharm Biomed Anal. 2018;150:208–19.CrossRefPubMedGoogle Scholar
- 20.Decreto 9 novembre 2015: Funzioni di Organismo statale per la cannabis previsto dagli articoli 23 e 28 della convenzione unica sugli stupefacenti del 1961, come modificata nel 1972. Available online: Molecules 2018, 23, 1230 21 of 22. http://www.gazzettaufficiale.it/eli/id/2015/11/30/15A08888/sg;jsessionid=p1rnwNujUKlqQ5azhA%20Q95A__.ntc-as3-guri2. Accessed 1 Oct 2018.
- 28.Fusco L, Vigevano F. Tonic spasm seizures: a particular and previously unreported type of seizure. Epilepsia. 1994;35(7):S87.Google Scholar
- 30.Trial of cannabidiol (CBD; GWP42003-P) for infantile spasms (GWPCARE7). https://clinicaltrials.gov/ct2/show/NCT02953548. Accessed on 1 Jan 2018.
- 34.Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–67.CrossRefPubMedGoogle Scholar